7.12

6.91% 0.46

Adial Pharmaceuticals Inc (ADIL)

Overview News Price History Financials Why ADIL Down? Discussions Forecast Stock Split

Adial Pharmaceuticals Inc stock is traded at $7.12, with a volume of 48,386. It is up +6.91% in the last 24 hours and up +87.37% over the past month. Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.

Previous Close:

$6.66

Open:

$6.61

24h Volume:

48,386

Relative Volume:

0.11

Market Cap:

$18.70M

Revenue:

Net Income/Loss:

$-7.77M

P/E Ratio:

-0.7189

EPS:

-9.9046

Net Cash Flow:

$-6.52M

1W Performance:

+27.14%

1M Performance:

+87.37%

6M Performance:

+257.79%

1Y Performance:

-17.78%

1-Day Range:

$6.27

$7.20

1-Week Range:

$5.30

$7.20

52-Week Range:

$1.31

$10.75

Adial Pharmaceuticals Inc Stock (ADIL) Company Profile

Name

Adial Pharmaceuticals Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

434-422-9800

Address

1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA

Employee

Twitter

@AdialPharma

Next Earnings Date

2026-08-12

Latest SEC Filings

ADIL's Discussions on Twitter

Compare ADIL vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADIL Adial Pharmaceuticals Inc	7.12	15.49M	0	-7.77M	-6.52M	-9.9046
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-14-24	Initiated	Rodman & Renshaw	Buy
Oct-30-18	Initiated	Maxim Group	Buy
Oct-11-18	Initiated	Dawson James	Buy

Adial Pharmaceuticals Inc Stock (ADIL) Latest News

Aug 21, 2026

Adial Pharmaceuticals Faces Nasdaq Listing Compliance Challenge - TipRanks

Aug 21, 2026

Adial Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Aug 21, 2026

Aug 17, 2026

Adial Pharmaceuticals (ADIL) Jumps 15% as Trading Volume AcceleratesFade Trade - vinanet.vn

Aug 17, 2026

Adial Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet

Aug 17, 2026

Adial Closes $32M Tranche of $64M Financing for Ulcerative Colitis Drug Development - Minichart

Aug 17, 2026

Form 8K Adial Pharmaceuticals Inc For: 17 August By Investing.com - Investing.com Nigeria

Aug 17, 2026

Weekly Recap: Cash shortfall, warrant reliance and CEO succession, CFO exit - TradingView

Aug 17, 2026

Adial Reports $52 Million Second-Quarter Net Loss After Azora Acquisition - Quiver Quantitative

Aug 17, 2026

Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update - The Manila Times

Aug 17, 2026

Aug 15, 2026

ADIL Q1 2026 Earnings: EPS Surprise Amid Revenue AbsenceDividend Growth Analysis - vinanet.vn

Aug 15, 2026

Adial Pharmaceuticals (ADIL) Slides 9.3% as Biotech Volatility ReturnsSector Leader Stocks - dars.gov.et

Aug 15, 2026

Aug 14, 2026

Adial Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 14, 2026

Adial Pharmaceuticals (NASDAQ: ADIL) lifts cash to $28.7M but flags going‑concern risk - Stock Titan

Aug 14, 2026

Aug 13, 2026

Form 8K Adial Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Nigeria

Aug 13, 2026

Adial Pharmaceuticals plans leadership changes tied to annual meeting vote - Investing.com

Aug 13, 2026

Adial Pharmaceuticals Plans Major Leadership and Board Transition - TipRanks

Aug 13, 2026

Adial PharmaceuticalsAs Of Aug 10, Anticipates Termination Of CEO Cary Claiborne After 2026 Annual Meeting - TradingView

Aug 13, 2026

Aug 12, 2026

ADIL Q1 2026 Earnings: Narrower-than-Expected Loss Delivers 46.85% Positive SurpriseCash Flow Report - Vinanet

Aug 12, 2026

Aug 11, 2026

Adial Pharmaceuticals Acquires Azora Therapeutics in Stock-and-Preferred Deal - Minichart

Aug 11, 2026

Adial Pharmaceuticals announces annual shareholder meeting - Bitget

Aug 11, 2026

Form 8K Adial Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Canada

Aug 11, 2026

Adial Pharmaceuticals (NASDAQ: ADIL) outlines Azora merger, heavy dilution and $53M share overhang - Stock Titan

Aug 11, 2026

Aug 07, 2026

Adial Pharmaceuticals Inc expected to post a loss of $1.03 a shareEarnings Preview - TradingView

Aug 07, 2026

Adial Pharmaceuticals (ADIL) Plunges 17% as Shares Test Key $3.78 Support LevelVolatility Breakout Picks - dars.gov.et

Aug 07, 2026

Aug 04, 2026

Adial Pharmaceuticals Price Target Announced at $11.00/Share by Alliance Global Partners - Moomoo

Aug 04, 2026

Adial Pharmaceuticals Initiated at Buy by Alliance Global Partners - Moomoo

Aug 04, 2026

Aug 03, 2026

A. G. P. Initiates Adial Pharmaceuticals(ADIL.US) With Buy Rating, Announces Target Price $11 - moomoo.com

Aug 03, 2026

Aug 01, 2026

ADIL Q1 2026 Earnings: EPS Beats Estimates Sharply, But Revenue Remains AbsentRevenue Growth Outlook - vinanet.vn

Aug 01, 2026

Jul 31, 2026

ADIL Q1 2026 Earnings: Narrower-than-Expected Loss Fuels 4.44% Share UptickFinancial Data - Vinanet

Jul 31, 2026

Jul 27, 2026